Rahman Md Motiar, Zhou Nan, Huang Jiandong
Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy of Sciences (CAS), Shenzhen 518055, China.
Faculty of Medicine, School of Biomedical Sciences, The University of Hong Kong, Hong Kong 999077, China.
Vaccines (Basel). 2021 Mar 11;9(3):244. doi: 10.3390/vaccines9030244.
The mRNA-based vaccine approach is a promising alternative to traditional vaccines due to its ability for prompt development, high potency, and potential for secure administration and low-cost production. Nonetheless, the application has still been limited by the instability as well as the ineffective delivery of mRNA in vivo. Current technological improvements have now mostly overcome these concerns, and manifold mRNA vaccine plans against various forms of malignancies and infectious ailments have reported inspiring outcomes in both humans and animal models. This article summarizes recent mRNA-based vaccine developments, advances of in vivo mRNA deliveries, reflects challenges and safety concerns, and future perspectives, in developing the mRNA vaccine platform for extensive therapeutic use.
基于信使核糖核酸（mRNA）的疫苗方法是传统疫苗的一种有前景的替代方案，因为它具有快速开发的能力、高效力，以及安全给药和低成本生产的潜力。尽管如此，该应用仍然受到mRNA在体内的不稳定性以及递送效率低下的限制。目前的技术改进大多已经克服了这些问题，并且针对各种形式的恶性肿瘤和传染病的多种mRNA疫苗计划在人类和动物模型中都报告了令人鼓舞的结果。本文总结了近期基于mRNA的疫苗进展、体内mRNA递送的进展，反映了在开发用于广泛治疗用途的mRNA疫苗平台方面的挑战、安全问题以及未来展望。
